Andrew Lewis, PhD, is Vice-President, Pharmaceutical Sciences at Quotient Sciences. Before that he was Director of Novel Drug Delivery Technologies at Ipsen until May 2016, where he led the development of new products utilising innovative delivery technologies for their peptides portfolio. Prior to joining Ipsen he helped set up and grow two venture capital-funded start-ups, RegenTec and Critical Pharmaceuticals, where he lead the development and commercialisation of novel technologies in the fields of tissue engineering and drug delivery, taking them from concept into clinical development. His work has focused on the delivery of macromolecules, particularly the sustained release and transmucosal delivery of proteins and peptides, and he has filed a number of patents in the field. He is a member of the Academy of Pharmaceutical Scientists of Great Britain, and has served on the Membership Committee, Board of Scientific Advisors and for the last three years he has been Director-at-Large of the Controlled Release Society.